Benzinga

Benzinga

Benzinga

mercoledì, settembre 09

Teladoc Health Inc

TDOCNYSE
Trade with Public
Trade with Public
$6.07
-0.19-3.12%
In chiusura: Sep 9, 5:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Teladoc Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teladoc Health (TDOC).

Price Target Range — 13 Quarters

Analyst Consensus — 20 Analysts

8Buy
12Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$9Upside to Avg. PT+46.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026CitigroupDaniel GrosslightPT CutNeutral$11→$8
Jul 30, 2026Canaccord GenuityRichard ClosePT CutBuy$11→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $11 to $7.5.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $10

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $11 to $10.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $7.5

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:TDOC) with a In-Line and lowers the price target from $10 to $7.5.
Benzinga Newsdesk

Synchrony Financial To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts change outlook on top names. Baird, Canaccord Genuity, Needham, Stifel, Truist Securities raise price targets. See analyst ratings.
Avi Kapoor

PRO
Canaccord Genuity Maintains Buy on Teladoc Health, Raises Price Target to $11

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and raises the price target from $10 to $11.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Teladoc Health, Raises Price Target to $7

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6 to $7.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved